Hygea Medical Completes Extended Series C Financing Round

(VCBeat) July. 13, 2021 -- Hygea Medical Technology Co., Ltd. ("Hygea Medical") recently announced the closing of a Series C+ financing, which is also the second round of financing completed by Hygea Medical in the first half of the year. This round is invested exclusively by Gaorong Capital. According to Hygea Medical, the fresh round of funding will be used towards the market and channel expansion, and the development and industrialization of a series of products.

Hygea Medical is one of the state-level high-tech enterprises, providing the research and development, production and sales of medical products and focusing on the development of innovative medical products for cancers with minimally invasive and low-temperature technology. Hygea Medical uses leading biomedical engineering technology and advanced intelligent instrument and equipment manufacturing and has successfully developed the minimally invasive cryotherapy system for complex tumors.

Based on its experience in the fields of low temperature and minimally invasive technology targeting cancers, Hygea Medical is committed to developing innovative medical technology in the direction of national strategy. The company is going to make a series of advanced solutions in the field of minimally invasive cancer diagnosis and treatment. The company takes "we only care about your health" as the belief and “climbing the peak of technology in the world, improving China's medical industry" as the mission, striving to become cancer diagnosis and treatment industry leader in China or even the world.

Huang Ganfu, founder of Hygea Medical, said, "The cooperation with Gaorong is very smooth, thanks for the trust of several seniors! Minimally invasive methods for cancer has rapidly grown into the fourth step of cancer treatment after surgery, radiotherapy and chemotherapy. The new generation of minimally invasive therapy for cancer represented by Kangbo Knife is leading the minimally invasive, accurate and intelligent treatment for cancer. With the help of Gaorong Capital and other new and existing shareholders, we look forward to accelerating the domestic and foreign layout of the product pipelines, promoting the wide application of digital medicine in the field of cancer diagnosis and treatment, continuously exploring in professional medical treatment and health products for the public, and building a leading platform enterprise."

Gaorong Capital is devoted to creating a better life through innovation. It is dedicated to identifying the leading founders and collaborating with them to achieve long-term value. Gaorong Capital focuses on the investment of innovations in technology and business models along with industrial integration.